Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.
Recommended Citation
Milling TJ, Jr., and Kaatz S. Preclinical and clinical data for factor xa and "universal" reversal agents Am J Med 2016;
Document Type
Article
Publication Date
11-1-2016
Publication Title
The American journal of medicine
Abstract
Oral Factor Xa (FXa) inhibitors, a growing class of direct-acting anticoagulants, are frequently used to prevent stroke and systemic embolism in patients with atrial fibrillation and to prevent and treat venous thromboembolism. These drugs reduce the risk of clotting at the expense of increasing the risk of bleeding, and currently they have no specific reversal agent. However, andexanet alfa, a recombinant modified FXa decoy molecule, is in a late-phase clinical trial in bleeding patients, and ciraparantag, a small molecule that appears to reverse many anticoagulants including the FXa inhibitors, is in development. This review summarizes the published data to date on both drugs, which have the potential to change the management approach to patients with FXa inhibitor-associated major hemorrhage.
Medical Subject Headings
Animals; Antidotes; Arginine; Atrial Fibrillation; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thromboembolism
PubMed ID
27575436
Volume
129
Issue
11S
First Page
80
